Insider · CIK 0002040022
Christopher Kim
Files at APUS (Apimeds Pharmaceuticals US, Inc.). First filing May 15, 2025, latest May 15, 2025.
In brief
Christopher Kim files SEC Form 4 as chair and director at APUS (Apimeds Pharmaceuticals US, Inc.). Since May 15, 2025, Christopher Kim has reported 1 open-market buy worth $50k and 0 open-market sells worth $0, the latest filed on May 15, 2025.
A track record needs three past buys with six months of prices behind them; Christopher Kim has 0, so none is measured yet.
The newest scored trade: bought $50k of APUS on May 13, 2025, filed May 15, 2025, scored 50 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
APUS: Apimeds Pharmaceuticals US, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Apimeds Pharmaceuticals US, Inc. | $50k 27,500 shares | - | - |
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 15, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | AGrant or award Stock Option (right to buy)derivative | +3,000 | $0.00 | $0 | 3,000 | Oct 17, 2025 |
| May 16, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | AGrant or award Common Stock, par value $0.01 per share | +250,000 | $0.00 | $0 | 277,500 | May 20, 2025 |
| May 13, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | POpen-market purchase Common Stock, par value $0.01 per share | +19,770 | $1.82 | $36k | 19,770 | May 15, 2025 |
| May 14, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | POpen-market purchase Common Stock, par value $0.01 per share | +7,730 | $1.86 | $14k | 27,500 | May 15, 2025 |
Questions about Christopher Kim
Answered from the filings on this page, as of the latest one.
Is Christopher Kim buying or selling?
Not in the last 12 months. Christopher Kim's latest open-market trade on SEC Form 4 was bought $50k of APUS on May 13, 2025.
How did Christopher Kim's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Christopher Kim has 0.
Where does Christopher Kim file Form 4?
Christopher Kim has filed Form 4 at APUS (Apimeds Pharmaceuticals US, Inc.) as Chairman and CMO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.